Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086034
Status:
COMPLETED
Last Update Posted:
2007-05-15
First Post:
2004-06-21
Brief Title:
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkins Lymphoma
Sponsor:
Pharmacyclics LLC
Organization:
Pharmacyclics LLC
Study Overview
Official Title:
Phase II Trial of Motexafin Gadolinium MGd in Patients With Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkins lymphoma NHL Secondly the safety and side effects of motexafin gadolinium will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None